Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Declines By 41.3%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 104,202 shares, a drop of 41.3% from the July 30th total of 177,544 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily volume of 316,969 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of Enlivex Therapeutics

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its holdings in Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after buying an additional 19,132 shares during the last quarter. Bank of America Corp DE increased its stake in Enlivex Therapeutics by 53.2% during the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after buying an additional 45,303 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Enlivex Therapeutics during the fourth quarter valued at approximately $33,000. Jane Street Group LLC raised its holdings in shares of Enlivex Therapeutics by 244.1% during the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after acquiring an additional 52,553 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics in the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

Analysts Set New Price Targets

ENLV has been the subject of several analyst reports. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Zacks Research upgraded shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $247.50.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ:ENLV traded down $0.10 during midday trading on Monday, reaching $1.25. 360,612 shares of the company’s stock traded hands, compared to its average volume of 101,036. The company has a fifty day simple moving average of $4.41 and a two-hundred day simple moving average of $10.40. Enlivex Therapeutics has a 1 year low of $1.15 and a 1 year high of $27.15. The company has a market cap of $21.86 million, a P/E ratio of -0.15 and a beta of 1.60.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.